Clinical trials: Adaptive Trial
Malignant Glioma, Recurrent Glioblastoma
Phase I/II Adaptive Randomized Trial of Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma
The goal of this Phase I portion of this clinical research study is to find the highest tolerable dose of bevacizumab with or without vorinostat, that can be given to patients with malignant gliomas.
- Trial name
- NCT01266031
- Testing
- vorinostat, bevacizumab
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- National Cancer Institute (NCI)
Suicide
Developing Adaptive Interventions for Suicidal College Students Seeking Treatment - SMART
This pilot study tested the feasibility of utilizing an adaptive intervention strategy for college students who are suicidal when first seeking treatment at a campus clinic.
- Trial name
- SMART (NCT02442869)
- Testing
- Stage 1 Treatment as usual (TAU), Stage 1 CAMS, Stage 2 CAMS
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- University of Nevada, Reno
Covid19
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
- Trial name
- ACTIV-4A (NCT04505774)
- Testing
- theraputic heparin, prophylactic heparin, P2Y12
- Where
- 101 sites in United States, Brazil and 2 more
- Volunteers
- 3,591 people
- Sponsor
- Matthew Neal MD
Type 1 Diabetes
Multi-center Trial in Adult and Pediatric Patients With Type 1 Diabetes Using Hybrid Closed Loop System and Control at Home
The purpose of this study is to evaluate the safety and effectiveness of the Hybrid Closed Loop system (HCL) in adult and pediatric patients with type 1 diabetes in the home setting.
- Trial name
- NCT02748018
- Testing
- 670G and 770G Insulin Pump, Subject's Current Diabetes Therapy
- Where
- 36 sites in United States, Canada and 7 more
- Volunteers
- 959 people
- Sponsor
- Medtronic MiniMed, Inc.
Asthma
AZD1419 Ph2a Study
Ph2a study planned to be run at approximately 16-18 sites in 4 EU countries (Denmark, Hungary, Poland and Sweden) enrolling approximately 170 patients to ensure 70 randomized patients with eosinophilic, moderate to severe asthma.
- Trial name
- INCONTRO (NCT02898662)
- Testing
- AZD1419
- Where
- 15 sites in Denmark, Hungary and 2 more
- Volunteers
- 81 people
- Sponsor
- AstraZeneca
Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8
ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy
This phase II trial studies two questions in patients with stage III NSCLC: 1) does it improve cancer control to add the drug Durvalumab, a type of immunotherapy, earlier in the treatment course; and 2) by intensifying treatment…
- Conditions
- Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
- Trial name
- NCT04372927
- Testing
- Cisplatin, Durvalumab, Etoposide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Washington
Acute Respiratory Distress Syndrome
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study.
- Trial name
- TRISTARDS (NCT04640194)
- Testing
- Standard of care, Alteplase low dose, Alteplase high dose
- Where
- 37 sites in Austria, Belgium and 11 more
- Volunteers
- 104 people
- Sponsor
- Boehringer Ingelheim
Chronic Cerebral Ischemia
Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia
The purpose of this study is to evaluate safety and efficacy of sequential treatment with Mexidol® in patients with chronic cerebral ischemia (CCI).
- Trial name
- MEMO (NCT06834490)
- Testing
- Mexidol
- Where
- 14 sites in Russia, Uzbekistan
- Volunteers
- 318 people
- Sponsor
- Pharmasoft
Acute Ischemic Stroke
Multi-arm Optimization of Stroke Thrombolysis
The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results…
- Trial name
- MOST (NCT03735979)
- Testing
- Argatroban, Eptifibatide
- Where
- 61 sites in United States
- Volunteers
- 514 people
- Sponsor
- Washington University School of Medicine
Cardiac Arrest
Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial
Cardiac arrest is a sudden, unexpected loss of heart function. Therapeutic hypothermia, in which the body's temperature is lowered and maintained several degrees below normal for a period of time, has been used to successfully…
- Trial name
- THAPCA-OH (NCT00878644)
- Testing
- Therapeutic Hypothermia, Therapeutic Normothermia
- Where
- 34 sites in United States, Canada
- Volunteers
- 295 people
- Sponsor
- University of Michigan
COVID 19
CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION
The objective of CROWN CORONATION is the prevention of symptomatic COVID-19 by using combinations of approved and safe repurposed interventions, with complementary mechanisms of action.
- Trial name
- CROWN CORONA (NCT04333732)
- Testing
- MR or M-M-R II ® vaccine
- Where
- 17 sites in United States, Ghana and 3 more
- Volunteers
- 3,411 people
- Sponsor
- Washington University School of Medicine
COVID-19
AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of AZD7442 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780437
- Testing
- AZD7442, Remdesivir
- Where
- 124 sites in United States, Denmark and 7 more
- Volunteers
- 1,455 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Attention-Deficit Hyperactivity Disorder
Pharmacokinetics of HLD200 in Children and Adolescents With ADHD
This study was designed to assess the pharmacokinetic effects of a single dose of HLD200 (methylphenidate hydrochloride) in children and adolescents with ADHD.
- Trial name
- NCT01907360
- Testing
- HLD200 (methylphenidate hydrochloride)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Ironshore Pharmaceuticals and Development, Inc
Head and Neck Neoplasm
Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer
Locoregional failure remains the principal mode of mortality in head and neck squamous cell carcinoma (HNSCC) treated with conventional chemoradiation therapy.
- Trial name
- DEHART (NCT04477759)
- Testing
- 50 Gy Radiation Therapy, 55 Gy Radiation Therapy, 60 Gy Radiation Therapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Medical College of Wisconsin
Dry Eye
The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease
The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in…
- Trial name
- NCT03879863
- Testing
- Reproxalap Ophthalmic Solution (0.25%) QID, Vehicle Ophthalmic Solution QID, Reproxalap Ophthalmic Solution (0.25%) QID to BID
- Where
- United States
- Volunteers
- 422 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Borderline Personality Disorder
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
- Trial name
- NCT04932291
- Testing
- vafidemstat
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 211 people
- Sponsor
- Oryzon Genomics S.A.
Myelodysplastic Syndromes
MBG453 in Lower Risk MDS
This research study is assessing the efficacy of MBG-453, a humanized monoclonal antibody, in treating myelodysplastic syndromes (MDS). The name of the study drug involved in this study is MBG453.
- Trial name
- NCT04823624
- Testing
- MBG453
- Where
- 3 sites in United States
- Volunteers
- 10 people
- Sponsor
- Massachusetts General Hospital
Rheumatoid Arthritis
A Phase II Trial Comparing Z-102 With Placebo In Patients With Moderate To Severe Rheumatoid Arthritis
Thus study will test an experimental drug called Z-102 (combination of prednisolone and dipyridamole) to treat patients with moderate to severe rheumatoid arthritis.
- Trial name
- Synergy (NCT01369745)
- Testing
- Prednisolone, dipyridamole, Prednisone
- Where
- United States
- Volunteers
- 294 people
- Sponsor
- Zalicus
Covid19
The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19
The study is a multicenter, adaptive, randomized, double-blinded and placebo-controlled Phase II/III trial, and will be conducted globally.
- Trial name
- NCT04644185
- Testing
- SCTA01
- Where
- 7 sites in United States, Argentina and 5 more
- Volunteers
- 102 people
- Sponsor
- Sinocelltech Ltd.
Glioblastoma Multiforme, Anaplastic Glioma
Vorinostat, Isotretinoin and Temozolomide in Adults With Recurrent Glioblastoma Multiforme (GBM)
The goal of this clinical research study is to learn if vorinostat when given with isotretinoin and temozolomide can help to control glioblastoma or gliosarcoma. The safety of these drug combinations will also be studied.
- Trial name
- NCT00555399
- Testing
- Vorinostat, Isotretinoin, Surgical Resection
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center